entertainment
Have you heard the news? I’m launching a weekly email newsletter starting on March 28. It’s called Adam’s Biotech Scorecard and it’s exclusively for STAT subscribers. One catch: We need you to sign up, which you can do here. What should you expect to see in my newsletter each week? Unfiltered, uncompromising, and (hopefully) valuable insight and analysis from the intersection of Wall Street and biotech. Plus, a few dashes of fun.
This week: A chat with Argenx CEO Tim Van Hauwermeiren, and updates on biotech PIPEs, Madrigal Pharmaceuticals, and Annovis Bio.
advertisement
The Belgian drugmaker Argenx is preparing for a commercial launch this summer that will expand the use of its IgG-lowering antibody Vyvgart to patients with chronic inflammatory demyelinating polyneuropathy, or CIDP, an autoimmune nerve disorder that causes people to lose feeling and muscle strength in the arms and legs.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log InNext article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
.png?upscale=true&width=1212&upscale=true&name=vTFET-vaccine-makers-surge-on-bird-flu-fears(3).png)
